✦ LIBER ✦

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

✍ Scribed by Bendell, Johanna C.; Ervin, Thomas J.; Gallinson, David; Singh, Jaswinder; Wallace, James A.; Saleh, Mansoor N.; Vallone, Marcy; Phan, See-Chun; Hack, Stephen P.

Book ID: 121002256
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 608 KB
Volume: 12
Category: Article
ISSN: 1533-0028
DOI: 10.1016/j.clcc.2013.04.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PEAK: A Randomized, Multicenter Phase II

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

✍ Schwartzberg, L. S.; Rivera, F.; Karthaus, M.; Fasola, G.; Canon, J.-L.; Hecht, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 520 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer

✍ Dreicer, Robert; Garcia, Jorge; Rini, Brian; Vogelzang, Nicholas; Srinivas, Sand 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 196 KB

Efficacy and safety of bevacizumab-based

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

✍ Ducreux, M.; Adenis, A.; Pignon, J.-P.; François, E.; Chauffert, B.; Ichanté, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 602 KB

Rationale and Design of MARQUEE: A Phase

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

✍ Giorgio V. Scagliotti; Silvia Novello; Joan H. Schiller; Vera Hirsh; Lecia V. Se 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 332 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB